Tag

Anti Obesity Drugs

All articles tagged with #anti obesity drugs

politics1 year ago•3 min saved

Biden's Plan Expands Medicare, Medicaid to Cover Anti-Obesity Drugs

The Biden administration has proposed expanding Medicare and Medicaid coverage to include costly anti-obesity drugs, potentially benefiting 7.4 million Americans. This move could significantly reduce out-of-pocket expenses for some Medicare beneficiaries, though the proposal's details and its future under the incoming Trump administration remain uncertain. The high cost of these drugs, such as Wegovy, has limited access, and the expansion could increase Medicare costs by billions annually. Currently, only a few states and job-based insurance plans cover these medications.

via CNN|

#anti-obesity-drugs #biden-administration #healthcare-costs

health2 years ago•3 min saved

The Role of Taste Buds in Controlling Appetite and Preventing Overeating

New research conducted on mice suggests that our brains rely on two separate pathways, one originating from the gut and the other from cells in the mouth responsible for taste perception, to regulate our sense of fullness and satiety. The study, conducted by researchers at the University of California San Francisco, provides insights into the mechanisms that control our appetite and could aid in the development of anti-obesity drugs. The findings indicate that there are two parallel tracks of satiety in the brainstem, with one controlling the pace of ingestion and the other determining the amount of food consumed. Further research is needed to confirm if humans have a similar system.

via Gizmodo|

#anti-obesity-drugs #fullness #health

healthcare2 years ago•2 min saved

"Wall Street's Skyrocketing Forecasts: Anti-Obesity Drug Sales Set to Surpass $100 Billion"

Wall Street analysts are raising their forecasts for the sales of anti-obesity drugs, such as Wegovy and Mounjaro, with estimates ranging from $71 billion to $200 billion by 2035. Guggenheim analyst Seamus Fernandez believes that GLP-1-based incretins will become the most prescribed drugs ever by 2031, with potential benefits for cardiovascular health, sleep apnea, and chronic kidney disease. Citi's forecast is more conservative, assuming a smaller patient population opting for the drugs. Despite high prices and limited insurance coverage, analysts expect these issues to be resolved over time, leading to peak sales of around $100 billion by 2030. Eli Lilly, which sells Mounjaro, is expected to capture a significant portion of this market.

via CNBC|

#anti-obesity-drugs #eli-lilly #glp-1-based-incretins

business2 years ago•3 min saved

The Profit Potential of Anti-Obesity Drugs for Food Makers and Investors

The demand for appetite suppressing anti-obesity drugs like Novo Nordisk's Wegovy presents opportunities for food manufacturers, despite an initial sell-off in shares of companies like Nestle. Investors believe that the market's reaction may be overdone, as the impact on long-term consumer habits is being extrapolated. While concerns exist about the potential impact on food sales, some investors see potential for major changes in the food and beverage industry, as well as other health-related stocks within the obesity industry. The limited availability of the drug and the development of companion products by food companies have led some investors to believe that the "miracle drugs" will not harm the industry in the long run. However, the affordability of these medications and the slow pace of behavior change may limit their widespread adoption.

via Reuters|

#anti-obesity-drugs #business #food-manufacturers

health2 years ago•4 min saved

Unveiling the Side Effects of Anti-Obesity Drugs

New anti-obesity drugs such as semaglutide and tirzepatide have shown promising results in clinical trials, leading to substantial weight loss and reduced cardiovascular risk. However, researchers are now investigating potential side effects, including gastrointestinal problems and loss of muscle mass. A recent study found that semaglutide was associated with a higher incidence of pancreatitis and gastroparesis compared to other weight-loss medications. Concerns about muscle-mass loss have prompted pharmaceutical companies to develop drugs that preserve muscle mass during weight loss. Specialists emphasize the importance of educating patients and providers about the risks and benefits of these medications, while acknowledging the need for further research in real-world conditions.

via Nature.com|

#anti-obesity-drugs #gastrointestinal-problems #health

health2 years ago•5 min saved

The Impact of Anti-Obesity Drugs on Patients and Industries

New anti-obesity drugs developed by Novo Nordisk and Eli Lilly have the potential to transform public health by reducing appetite and helping people feel fuller for longer. These drugs, known as GLP-1 drugs, have already seen soaring sales and are expected to have a significant impact on the medical, food, and fitness industries. However, their adoption remains uncertain due to high costs and harsh side effects. If widely adopted, these drugs could disrupt industries such as snacks, fast food, medical devices, weight management treatments, and addiction-related industries. While some companies may benefit from the shift in consumer spending, others may see their markets shrink.

via Reuters|

#anti-obesity-drugs #health #market-disruption